| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g | |||
| 5g | |||
| 10g | |||
| Other Sizes |
| Targets |
HCT-15 cells (IC50 = 2.5 μM)
Kinetin Riboside does not have a single defined pharmacological target. As a cytokinin analog, it interacts with cytokinin signaling pathways in plants. In mammalian cells, it induces apoptosis through the production of reactive oxygen species (ROS) and cellular ATP depletion. The compound's anticancer activity is mediated through induction of apoptosis in various cancer cell types. Its mechanism of action involves the generation of oxidative stress and disruption of cellular energy metabolism, leading to programmed cell death. The compound's activity as a cytokinin analog also makes it useful for studying plant development and growth regulation. |
|---|---|
| ln Vitro |
Kinetin riboside exhibits antiproliferative and apoptogenic activity against different human cancer cell lines. The proliferation of human colon cancer HCT-15 cells can be inhibited by kinetin riboside in a dose-dependent manner (IC50=2.5 μM)[1]. In HeLa and mouse melanoma B16F-10 cells, kinetoin riboside triggers apoptosis. The release of cytochrome c and activation of caspase-3 are caused by kinetoin riboside, which also alters the potential of the mitochondrial membrane. Under kinetin riboside exposure, Bcl-2 is down-regulated and Bad are up-regulated[2].
Kinetin Riboside induces the production of reactive oxygen species (ROS), cellular ATP depletion, and apoptosis in HepG2 cells. It exhibits cytotoxic and antiproliferative activities and inhibits the proliferation of HCT-15 cells with an IC50 of 2.5 µM. The compound shows anticancer activity by inducing apoptosis in various types of cancers including myeloid leukemia cells, mouse melanoma B16F-10 cells, and plant tumor cells. Its ability to induce ROS production and ATP depletion suggests a mechanism involving mitochondrial dysfunction and oxidative stress. |
| ln Vivo |
Kinetin riboside significantly slows the growth of tumors. At 40 mg/kg, the strongest anti-melanoma response is elicited[2].
No specific in vivo activity data is publicly available for Kinetin Riboside. As an anticancer compound, it would be expected to have anti-tumor activity in vivo. The compound's ability to induce apoptosis in various cancer cell types suggests potential efficacy in cancer models. However, specific in vivo studies have not been detailed in the available literature. The compound is also a plant growth regulator, indicating potential applications in agriculture. |
| Enzyme Assay |
No specific non-cell assay protocol is available for Kinetin Riboside. For studying the compound's effects, various cell-free assays could be employed depending on the specific activity being investigated. For antioxidant or pro-oxidant activity, assays measuring ROS production or antioxidant capacity could be used. For studying apoptosis, caspase activity assays or DNA fragmentation assays could be employed. However, specific protocols have not been detailed in the available literature.
|
| Cell Assay |
HeLa and mouse melanoma B16F-10 cells are treated with 5, 10, 20 μM kinetin riboside for 48 h. Cells are kept at 37°C for 4 hours after adding 15 μL of MTT solution (5 mg/mL) to each well. After that, 100 microliters of solubilizing solution are added. A measurement of 490 nm absorbance is made following an overnight incubation at room temperature[2].
No specific cell-based assay protocol is available for Kinetin Riboside. For anticancer studies, standard cell-based assays involve treatment of cancer cell lines (e.g., HepG2, HCT-15, myeloid leukemia cells, B16F-10 melanoma cells) with Kinetin Riboside for 24-72 hours. Cell viability is measured using MTT or CellTiter-Glo assays to determine IC50 values. Apoptosis is assessed by Annexin V/PI staining, caspase activity assays, or DNA fragmentation. ROS production is measured using fluorescent probes such as DCFH-DA. ATP levels are measured using luminescent ATP assays. |
| Animal Protocol |
No specific animal protocol is available for Kinetin Riboside. For anticancer studies, standard in vivo models include xenograft models using cancer cell lines. Kinetin Riboside is administered (route and dose to be determined) for 2-4 weeks. Tumor growth, apoptosis markers, and survival are assessed. For plant studies, the compound can be applied to plants to study its effects on growth and development. However, specific protocols have not been detailed in the available literature.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data is publicly available for Kinetin Riboside. The compound has a molecular weight of 347.33 and formula C15H17N5O5. It is soluble in DMSO at ≥46.7 mg/mL, insoluble in ethanol, and soluble in water at ≥1.94 mg/mL with ultrasonic assistance. As a nucleoside derivative, it would be expected to have reasonable cell permeability. Comprehensive pharmacokinetic studies would be required for therapeutic development.
|
| Toxicity/Toxicokinetics |
No detailed toxicology data is publicly available for Kinetin Riboside. As a research compound, standard preclinical toxicology would be required for therapeutic development. The compound's ability to induce ROS production and ATP depletion suggests potential for cytotoxicity that would need to be carefully evaluated. The compound is for research use only and not for therapeutic applications.
|
| References |
|
| Additional Infomation |
(2R,3R,4S,5R)-2-[6-(2-furanmethylamino)-9-purine]-5-(hydroxymethyl)oxacyclopentane-3,4-diol is a purine nucleoside. It has been reported that coconuts and beets contain kinetin nucleosides, and relevant data exists.
Kinetin Riboside is also known as N6-Furfuryladenosine and Furfurylaminopurineriboside. It has the molecular formula C15H17N5O5 and molecular weight 347.33. The chemical name is (2R,3R,4S,5R)-2-(6-((Furan-2-ylmethyl)amino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol. It is a purine derivative and nucleoside with anticancer activity and a plant growth regulator. The compound inhibits the proliferation of HCT-15 cells with an IC50 of 2.5 µM. No clinical trial status has been identified. |
| Molecular Formula |
C15H17N5O5
|
|---|---|
| Molecular Weight |
347.32598
|
| Exact Mass |
347.122
|
| Elemental Analysis |
C, 51.87; H, 4.93; N, 20.16; O, 23.03
|
| CAS # |
4338-47-0
|
| Related CAS # |
4338-47-0
|
| PubChem CID |
20345
|
| Appearance |
White to off-white solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
683.7±65.0 °C at 760 mmHg
|
| Melting Point |
152-154ºC
|
| Flash Point |
367.3±34.3 °C
|
| Vapour Pressure |
0.0±2.2 mmHg at 25°C
|
| Index of Refraction |
1.798
|
| LogP |
0.2
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
25
|
| Complexity |
460
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
OC[C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C2N=CN=C3NCC4=CC=CO4)O1)O)O
|
| InChi Key |
CAGLGYNQQSIUGX-SDBHATRESA-N
|
| InChi Code |
InChI=1S/C15H17N5O5/c21-5-9-11(22)12(23)15(25-9)20-7-19-10-13(17-6-18-14(10)20)16-4-8-2-1-3-24-8/h1-3,6-7,9,11-12,15,21-23H,4-5H2,(H,16,17,18)/t9-,11-,12-,15-/m1/s1
|
| Chemical Name |
(2R,3R,4S,5R)-2-[6-(furan-2-ylmethylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
|
| Synonyms |
Kinetin Riboside
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~719.78 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.99 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.99 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.99 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8791 mL | 14.3955 mL | 28.7911 mL | |
| 5 mM | 0.5758 mL | 2.8791 mL | 5.7582 mL | |
| 10 mM | 0.2879 mL | 1.4396 mL | 2.8791 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
